ReadYourDNA

Teneligliptin (Tenelia)

Raw research findings for this medication. Mostly single studies, not curated or confirmed robust.

About Teneligliptin

What it is

Teneligliptin is a DPP-4 inhibitor: it blocks the enzyme that breaks down incretins, gut hormones such as GLP-1 that tell the pancreas to release insulin after a meal. It is used for type 2 diabetes, mainly in Japan, Korea, India and other Asian countries, and is not marketed in the US or Europe. It is sold as Tenelia, among other names.

How genes come into it

Teneligliptin is cleared partly by the kidneys and partly by the liver enzymes CYP3A4 and FMO3. The few gene studies on it, from Asia, looked at FMO3 and CYP3A4 for its blood levels and at IL6 for response. The findings come from a few studies, and there is no CPIC or DPWG guideline.

What research found

Every published finding on gene variants and Teneligliptin. Upload your DNA file to see which of these rows apply to you.

Metabolism (4 findings)

Studies of how quickly the body processes this medication.

CYP3A4 rs2242480: Genotypes CT + TT is associated with decreased concentrations of teneligliptin in men as compared to genotype CC.

FMO3 rs2266780: Genotypes AG + GG is associated with decreased clearance of teneligliptin in men as compared to genotype AA.

FMO3 rs2266782: Genotypes AG + GG is associated with decreased clearance of teneligliptin in men as compared to genotype AA.

FMO3 rs909530: Genotypes CT + TT is associated with decreased clearance of teneligliptin in men as compared to genotype CC.

Response (2 findings)

Studies of how well it worked in people carrying a variant.

rs2097677: Genotypes AA + AG is associated with increased response to alogliptin, linagliptin, sitagliptin, teneligliptin or vildagliptin in people with Diabetes Mellitus, Type 2 as compared to genotype GG.

IL6 rs1800796: Genotypes CG + GG is associated with increased response to alogliptin, linagliptin, sitagliptin, teneligliptin or vildagliptin in people with Diabetes Mellitus, Type 2 as compared to genotype CC.

Study findings and evidence levels: PharmGKB (CC BY-SA 4.0). Guidelines: CPIC and DPWG, as bundled in PharmCAT. Most studies were done mainly in people of European ancestry.

Related Drugs

More drugs from the same category

DPP-4 Inhibitors (class) (DPP-4 Inhibitors)

Galvus (DPP-4 Inhibitors)

Januvia (DPP-4 Inhibitors)

Not a prescribing recommendation. This page is educational information about pharmacogenomic research and clinical guidelines - it is not medical or dosing advice, and not a prediction of how any medication will work for you. Never start, stop, or change a medication or dose based on it; talk to your doctor or pharmacist, who can order clinical-grade testing if appropriate.

Back to Medications

Content updated September 2026.

ReadYourDNA provides educational interpretation of DNA data you already have. It is not diagnostic, not a substitute for professional medical advice, diagnosis, or treatment, and is not intended to diagnose, treat, cure, or prevent any disease. Talk to a clinician before acting on any result.

Raw DNA Data Reports for 23andMe & AncestryDNA · About ReadYourDNA · FAQ · Methodology & Science · Pricing · Support and complaints · Legal & Contact · Health Traits · Pharmacogenomics · Carrier Status · Variant Explorer · The Human Karyotype · Privacy Policy · Terms of Service · Accessibility · Consumer Health Data Privacy · Your Privacy Choices · Editorial Standards · Your Data, Checkable · Sample Report · ReadYourDNA and Promethease compared · What is inside a 23andMe raw data file · What is inside an AncestryDNA raw data file · What a chatbot can and cannot do with your raw DNA file · Where a raw DNA file can still be uploaded in 2026

Written, maintained and operated by Martin Pechhacker, sole proprietor, Vienna, Austria. Trade register GISA 40064420. support@readyourdna.com